The Story of Serum Prothrombin Conversion Accelerator, Proconvertin, Stable Factor, Cothromboplastin, Prothrombin Accelerator or Autoprothrombin I, and Their Subsequent Merging into Factor VII

 

 Buy Article Permissions and Reprints

Abstract

Factor VII (FVII) deficiency is one of the two congenital coagulation disorders that was not discovered by the description of a new bleeding patient whose clotting pattern did not fit the blood coagulation knowledge of the time (the other is factor XIII deficiency). The existence of an additional factor capable of accelerating the conversion of prothrombin into thrombin was suspected before 1951, the year in which the first family with FVII deficiency was discovered. As several investigators were involved in the discovery of FVII deficiency from both sides of the Atlantic, several different names were tentatively suggested to define this entity, namely stable factor (in contrast with labile factor or FV), cothromboplastin, proconvertin, serum prothrombin conversion accelerator, prothrombin acceleration, and autoprothrombin I. The last term was proposed by those who denied the existence of this new entity, which was instead considered to be a derivate of prothrombin activation, namely autoprothrombin. The description of several families, from all over the world, of the same defect, however clearly demonstrated the singularity of the condition. Factor VII was then proposed to define this protein. In subsequent years, several variants were described with peculiar reactivity toward tissue thromboplastins of different origin. Molecular biology techniques demonstrated several gene mutations, usually missense mutations, often involving exon 8 of the FVII gene. Later studies dealt with the relation of FVII with tissue factor and activated FVII (FVIIa). The evaluation of circulating FVIIa was made possible by the use of a truncated form of tissue factor, which is only sensitive to FVIIa present in the circulation. The development of FVII concentrates, both plasma derived and recombinant, has facilitated therapeutic management of FVII-deficient patients. The use of FVIIa concentrates was noted to be associated with the occasional occurrence of thrombotic events, mainly venous. Total or partial liver transplants have been performed with success in these patients and have “cured” their deficiencies. Prenatal diagnosis has also been performed and recent research involves the development of inhibitors of FVII + tissue factor complex or of FVIIa. This approach, if successful, could provide another antithrombotic therapeutics tool. The story of FVII well summarizes the efforts of both theoretical and clinical approaches in the characterization of a coagulation disorder, that is, among the rare bleeding conditions, most frequently encountered in clinical practice.

• References

• 1 Quick AJ. Stanley- Brown M., Bancroft F.W. A study of the coagulation defect in haemophilia and in Jaundice. Am J Med Sci 1935; 190 (2) 501-506
  CrossrefPubMedGoogle Scholar
• 2 Rafe F, Salomon F. Uber faserstoffmangee in Blute bei einem Falle von Hemophilia- Arck Kein. Med. 1920; 132 (5) 240-244
  PubMedGoogle Scholar
• 3 Quick AJ. Congenital hypoprothrombinaemia and pseudo-hypoprothrombinaemia. Lancet 1947; 2 (6472) 379-382
  PubMedGoogle Scholar
• 4 Owen CA, Bowie EJ, Thompson JH. The Diagnosis of Bleeding Disorders. 2nd ed. New York, NY: Little Brown Co.; 1975: 26
  Google Scholar
• 5 Owen CA, Bollman JL. Prothrombin conversion factor of dicumarol plasma. Proc Soc Exp Biol Med 1948; 67 (2) 231-234
  CrossrefPubMedGoogle Scholar
• 6 Owen Jr CA, Magath TB, Bollman JL. Prothrombin conversion factors in blood coagulation. Am J Physiol 1951; 166 (1) 1-11
  PubMedGoogle Scholar
• 7 Owren PA. Parahaemophilia; haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet 1947; 1 (6449) 446-448
  PubMedGoogle Scholar
• 8 Alexander B, Goldstein R, Landwehr G, Cook CD. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest 1951; 30 (6) 596-608
  CrossrefPubMedGoogle Scholar
• 9 Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (factor VII). Acta Haematol 1951; 6 (1) 1-18
  CrossrefPubMedGoogle Scholar
• 10 Girolami A, Cosi E, Sambado L, Girolami B, Randi ML. The complex history of the discovery and characterisation of congenital Factor X deficiency. Semin Thromb Hemost 2015; ; current issue
  PubMedGoogle Scholar
• 11 Owren PA. Prothrombin and accessory factors; clinical significance. Am J Med 1953; 14 (2) 201-215
  CrossrefPubMedGoogle Scholar
• 12 Stormorken H, Paul A. Owen. The Golden Age of Hemostasis. Gazette Bok, Oslo; 2005: 102
  Google Scholar
• 13 Aas K. Prokonvertin of Konvertin. Thesis, Oslo University, Norway; 1952
  Google Scholar
• 14 Girolami A, Brunetti A, Cella G, Bareggi G, Vingolini L, Cafiero F. La ipoconvertinemia-. Biol Lat 1972; 23: 397-434
  PubMedGoogle Scholar
• 15 Lewis J, Fresh J, Ferguson J. Congenital hypoconvertianemia. Proc Soc Exp Biol Med 1953; 84 (3) 651-654
  CrossrefPubMedGoogle Scholar
• 16 White II GC. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost 2003; 1 (11) 2267-2270
  CrossrefPubMedGoogle Scholar
• 17 Quick AJ. On the constitution of prothrombin. Am J Physiol 1943; 140: 212-220
  PubMedGoogle Scholar
• 18 Mariani G, Bernardi F. Factor VII deficiency Sem. Thromb Haemost 2009; 35 (4) 400-406
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Perry DJ. Factor VII deficiency. Br J Haematol 2002; 118 (3) 689-700
  CrossrefPubMedGoogle Scholar
• 20 Girolami A, Patrassi GM, Fabris F, Vicarioto MA. Factor VII Mangel und varianten. Haemostaseologie 1984; 3 (4) 98-104
  PubMedGoogle Scholar
• 21 De Nicola P. Factor VII (SPCA): its physiopathologic significance. Blood 1953; 8 (10) 947-954
  PubMedGoogle Scholar
• 22 Girolami A, Scandellari R, Scapin M, Vettore S. Congenital bleeding disorders of the vitamin K-dependent clotting factors. Vitam Horm 2008; 78 (1) 281-374
  PubMedGoogle Scholar
• 23 Triplett DA, Brandt JT, Batard MA, Dixon JL, Fair DS. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood 1985; 66 (6) 1284-1287
  PubMedGoogle Scholar
• 24 Herrmann FH, Wulff K, Auerswald G , et al; Greifswald Factor FVII Deficiency Study Group. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia 2009; 15 (1) 267-280
  CrossrefPubMedGoogle Scholar
• 25 Millar DS, Kemball-Cook G, McVey JH , et al. Molecular analysis of the genotype-phenotype relationship in factor VII deficiency. Hum Genet 2000; 107 (4) 327-342
  CrossrefPubMedGoogle Scholar
• 26 Peyvandi F, Jenkins PV, Mannucci PM , et al. Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thromb Haemost 2000; 84 (2) 250-257
  PubMedGoogle Scholar
• 27 Chaing S, Clarke B, Sridhara S , et al. Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood 1994; 83 (12) 3524-3535
  PubMedGoogle Scholar
• 28 Tamary H, Fromovich-Amit Y, Shalmon L , et al. Molecular characterization of four novel mutations causing factor VII deficiency. Hematol J 2000; 1 (6) 382-389
  CrossrefPubMedGoogle Scholar
• 29 Clarke BJ, Ofosu FA, Sridhara S, Bona RD, Rickles FR, Blajchman MA. The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor. FEBS Lett 1992; 298 (2-3) 206-210
  CrossrefPubMedGoogle Scholar
• 30 Ware AG, Seegers WH. Plasma accelerator globulin; partial purification, quantitative determination, and properties. J Biol Chem 1948; 172 (2) 699-705
  PubMedGoogle Scholar
• 31 Seegers WH, Alkjaersig N, Johnson SA. Formation of autoprothrombin in solutions containing purified prothrombin and purified platelet factor 3. Am J Physiol 1955; 181 (3) 589-594
  PubMedGoogle Scholar
• 32 McFarlane RG, The theory of blood coagulation in human blood coagulation, haemostasis and thrombosis. In: Biggs R. , ed. Blackwell Science Publishers: Oxford; 1972. pag.23
  Google Scholar
• 33 Denson KW, Conard J, Samama M. Genetic variants of factor VII. Lancet 1972; 1 (7762) 1234
  PubMedGoogle Scholar
• 34 Goodnight Jr SH, Feinstein DI, Osterud B, Rapaport SI. Factor VII antibody-neutralizing material in hereditary and acquired factor VII deficiency. Blood 1971; 38 (1) 1-8
  PubMedGoogle Scholar
• 35 Girolami A, Fabris F, Dal Bo Zanon R, Ghiotto G, Burul A. Factor VII Padua: a congenital coagulation disorder due to an abnormal factor VII with a peculiar activation pattern. J Lab Clin Med 1978; 91 (3) 387-395
  PubMedGoogle Scholar
• 36 Girolami A, Scarparo P, Bonamigo E, Treleani M, Lombardi AM. Homozygous FVII deficiencies with different reactivity towards tissue thromboplastins of different origin. Hematology 2012; 17 (6) 350-354
  CrossrefPubMedGoogle Scholar
• 37 Matsushita T, Kojima T, Emi N, Takahashi I, Saito H. Impaired human tissue factor-mediated activity in blood clotting factor VIINagoya (Arg304—>Trp). Evidence that a region in the catalytic domain of factor VII is important for the association with tissue factor. J Biol Chem 1994; 269 (10) 7355-7363
  PubMedGoogle Scholar
• 38 Takamiya O, Abe S, Yoshioka A, Nakajima K, McVey JH, Tuddenham EG. Factor VII Shinjo: a dysfunctional factor VII variant homozygous for the substitution Gln for Arg at position 79. Haemostasis 1995; 25 (3) 89-97
  PubMedGoogle Scholar
• 39 Takamiya O, Takeuchi S. Dysfunctional factor VII variant (FVII Tondabayashi) with R79Q: determination of mutated site with monoclonal anti-human factor VII antibody (B101/B1). Clin Chem 1998; 44 (9) 1993-1995
  PubMedGoogle Scholar
• 40 Girolami A, Treleani M, Scarparo P, Bonamigo E, Lombardi AM. Considerations on a tentative classification of FVII deficiency suited for practical clinical purposes. Clin Appl Thromb Hemost 2012; 18 (6) 654-657
  CrossrefPubMedGoogle Scholar
• 41 Giansily-Blaizot M, Schved JF. Potential predictors of bleeding risk in inherited factorVII deficiency. Clinical, biological and molecular criteria. Thromb Haemost 2005; 94 (5) 901-906
  PubMedGoogle Scholar
• 42 Girolami A, Tezza F, Scandellari R, Vettore S, Girolami B. Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature. J Thromb Thrombolysis 2010; 30 (2) 172-178
  CrossrefPubMedGoogle Scholar
• 43 Girolami A, Berti de Marinis G, Vettore S, Girolami B. Congenital FVII deficiency and pulmonary embolism: a critical appraisal of all reported cases. Clin Appl Thromb Hemost 2013; 19 (1) 55-59
  CrossrefPubMedGoogle Scholar
• 44 Girolami A, Sambado L, Bonamigo E, Ferrari S, Lombardi AM. Pathogenetic role of Factor VII deficiency and thrombosis in cross-reactive material positive patients. Lab Hematol 2013; 19 (4) 17-21
  CrossrefPubMedGoogle Scholar
• 45 Girolami A, Berti de Marinis G, Bertozzi I, Peroni E, Tasinato V, Lombardi AM. Discrepant ratios of arterial vs. venous thrombosis in hemophilias A and B as compared to FVII deficiency. Eur J Haematol 2013; 91 (2) 152-156
  CrossrefPubMedGoogle Scholar
• 46 Greene LA, Goldenberg NA, Simpson ML , et al. Use of global assays to understand clinical phenotype in congenital factor VII deficiency. Haemophilia 2013; 19 (5) 765-772
  CrossrefPubMedGoogle Scholar
• 47 James HL, Girolami A, Hubbard JG, Kumar A, Fair DS. The dysfunction of coagulation factor VII Padua results from substitution of arginine-304 by glutamine. Biochim Biophys Acta 1993; 1172 (3) 301-305
  CrossrefPubMedGoogle Scholar
• 48 Mota L, Shetty S, Idicula-Thomas S, Ghosh K. Phenotypic and genotypic characterization of Factor VII deficiency patients from Western India. Clin Chim Acta 2009; 409 (1-2) 106-111
  CrossrefPubMedGoogle Scholar
• 49 Millar DS, Cooper DN, Kakkar VV, Schwartz M, Scheibel E. Prenatal exclusion of severe factor VII deficiency by DNA sequencing. Lancet 1992; 339 (8805) 1359
  PubMedGoogle Scholar
• 50 Giansily-Blaizot M, Aguilar-Martinez P, Mazurier C , et al. Prenatal diagnosis of severe factor VII deficiency using mutation detection and linkage analysis. Br J Haematol 2001; 112 (1) 251-252
  CrossrefPubMedGoogle Scholar
• 51 Ariffin H, Millar DS, Cooper DN, Chow T, Lin HP. Prenatal exclusion of severe factor VII deficiency. J Pediatr Hematol Oncol 2003; 25 (5) 418-420
  CrossrefPubMedGoogle Scholar
• 52 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81 (3) 734-744
  Google Scholar
• 53 O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295 (3) 293-298
  CrossrefPubMedGoogle Scholar
• 54 Levi D, Pefkarou A, Fort JA, DeFaria W, Tzakis AG. Liver transplantation for factor VII deficiency. Transplantation 2001; 72 (11) 1836-1837
  CrossrefPubMedGoogle Scholar
• 55 Muiesan P, Jassem W, Girlanda R , et al. Segmental liver transplantation from non-heart beating donors—an early experience with implications for the future. Am J Transplant 2006; 6 (5 Pt 1) 1012-1016
  CrossrefPubMedGoogle Scholar
• 56 Dhawan A, Mitry RR, Hughes RD , et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78 (12) 1812-1814
  CrossrefPubMedGoogle Scholar
• 57 Guy S, Magliocca J, Fruchtman S , et al. Trasmission of factor VII deficiency through liver transplantation. Transpl Int 1999; 12 (4) 278-280
  CrossrefPubMedGoogle Scholar
• 58 Girolami A, Ruzzon E, Tezza F, Allemand E, Vettore S. Congenital combined defects of factor VII: a critical review. Acta Haematol 2007; 117 (1) 51-56
  CrossrefPubMedGoogle Scholar
• 59 Pfeiffer RA, Ott R, Gilgenkrantz S, Alexandre P. Deficiency of coagulation factors VII and X associated with deletion of a chromosome 13 (q34). Evidence from two cases with 46,XY,t(13;Y)(q11;q34). Hum Genet 1982; 62 (4) 358-360
  CrossrefPubMedGoogle Scholar
• 60 Boxus G, Slacmeulder M, Ninane J. Combined hereditary deficiency in factors VII and X revealed by a prolonged partial thromboplastin time [in French]. Arch Pediatr 1997; 4 (1) 44-47
  PubMedGoogle Scholar
• 61 Menegatti M, Karimi M, Garagiola I, Mannucci P, Peyvandi F. A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency. Am J Hematol 2004; 77 (1) 90-91
  CrossrefPubMedGoogle Scholar
• 62 Seligsohn U, Shani M, Ramot B, Adam A, Sheba C. Dubin-Johnson syndrome in Israel. II. Association with factor-VII deficiency. Q J Med 1970; 39 (156) 569-584
  PubMedGoogle Scholar
• 63 Seligsohn U, Shani M, Ramot B. Gilbert syndrome and factor-VII deficiency. Lancet 1970; 1 (7661) 1398
  PubMedGoogle Scholar
• 64 Mor-Cohen R, Zivelin A, Fromovich-Amit Y, Kovalski V, Rosenberg N, Seligsohn U. Age estimates of ancestral mutations causing factor VII deficiency and Dubin-Johnson syndrome in Iranian and Moroccan Jews are consistent with ancient Jewish migrations. Blood Coagul Fibrinolysis 2007; 18 (2) 139-144
  CrossrefPubMedGoogle Scholar
• 65 Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002; 30 (5, Suppl): S241-S250
  CrossrefPubMedGoogle Scholar
• 66 Shirk RA, Vlasuk GP. Inhibitors of Factor VIIa/tissue factor. Arterioscler Thromb Vasc Biol 2007; 27 (9) 1895-1900
  CrossrefPubMedGoogle Scholar
• 67 Price GC, Thompson SA, Kam PC. Tissue factor and tissue factor pathway inhibitor. Anaesthesia 2004; 59 (5) 483-492
  CrossrefPubMedGoogle Scholar
• 68 Triplett DA. The extrinsic system. Clin Lab Med 1984; 4 (2) 221-244
  PubMedGoogle Scholar
• 69 Sridhara S, Clarke BJ, Blajchman MA. Arginine-79 in the first epidermal growth factor domain of factor VII is essential for the interaction with tissue factor. Blood Coagul Fibrinolysis 1993; 4 (3) 505-508
  CrossrefPubMedGoogle Scholar
• 70 O'Brien DP, Kemball-Cook G, Hutchinson AM , et al. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry 1994; 33 (47) 14162-14169
  CrossrefPubMedGoogle Scholar
• 71 Dickinson CD, Kelly CR, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. Proc Natl Acad Sci U S A 1996; 93 (25) 14379-14384
  CrossrefPubMedGoogle Scholar
• 72 Abraham E, Reinhart K, Opal S , et al; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290 (2) 238-247
  Google Scholar
• 73 Bernardi F, Marchetti G, Pinotti M. Factor VII contribute about one third of the total factor VII Level variation in plasma. Atheroscler Thromb Vasca Boil 1996; 16 (1) 72-76
  PubMedGoogle Scholar
• 74 Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta 2003; 330 (1-2) 31-55
  CrossrefPubMedGoogle Scholar
• 75 Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11 (3) 540-546
  CrossrefPubMedGoogle Scholar
• 76 Etscheid M, Muhl L, Pons D, Jukema JW, König H, Kanse SM. The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity. Thromb Res 2012; 130 (6) 935-941
  CrossrefPubMedGoogle Scholar
• 77 Etscheid M, Muhl L, Pons D, Jukema JW, König H, Kanse SM. The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity. Thromb Res 2012; 130 (6) 935-941
  CrossrefPubMedGoogle Scholar
• 78 Lwaleed BA, Goyal A, Delves G, Gossai S, Greenfield RS, Cooper AJ. Seminal factor VII and factor VIIa: supporting evidence for the presence of an active tissue factor-dependent coagulation pathway in human semen. Int J Androl 2007; 30 (6) 543-549
  CrossrefPubMedGoogle Scholar
• 79 Branchini A, Baroni M, Pfeiffer C , et al. Coagulation factor VII variants resistant to inhibitory antibodies. Thromb Haemost 2014; 112 (5) 972-980
  CrossrefPubMedGoogle Scholar
• 80 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977; 74 (12) 5260-5264
  CrossrefPubMedGoogle Scholar